Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib rollover study in B-cell malignancies
jRCT2021220038Phase 2Active, not recruiting
- Sponsor
- Incyte
- Start
- Sep 2022
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of parsaclisib in B-cell malignancy (4 arms), sponsored by Incyte. Primary endpoint: Incidence of treatment-emergent adverse events. Started Sep 2022; status: active, not recruiting.
02
Drugs
parsaclisib
03
Conditions
B-cell malignancy
Beyond the preview
Go deeper on jRCT2021220038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021220038.